Hisamitsu's terbinafine patch set for Phase III
This article was originally published in Scrip
You may also be interested in...
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.
Full, planned acquisition of Tokyo-based operation will give US biotech giant a firmer foothold in key market and new platform for Otezla growth.